ALNYLAM PHARMACEUTICALS, INC. (ALNY)
Every FINRA and SEC series the site collects for ALNYLAM PHARMACEUTICALS, INC.: short interest with days to cover, daily short sale volume, fails to deliver and Form 4 insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
4.8M
Short interest
settlement 2026-08-14
2.4
Days to cover
-0.7% vs prior
67.2%
Short share of volume
2026-09-11
2
Fails to deliver
settlement 2026-08-12
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-09-11.
Short interest
FINRA, twice a month; the last 12 months shown, all 48 settlements in the JSONAs of 14 August 2026, short interest in ALNY is 4,770,978 shares, down 1,002,395 shares over the last month. Over the last 48 readings it ranged from 2,493,180 shares (28 February 2025) to 5,799,788 shares (30 June 2026). At the reported average volume of 2.0M shares a day that is 2.4 days to cover.
Embed this chartfree, with the attribution line it carries
<iframe src="https://xoomar.com/embed/stocks/alny" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-14 | 4,770,978 | -0.7% | 2,018,399 | 2.36 |
| 2026-07-31 | 4,803,194 | -16.8% | 2,204,446 | 2.18 |
| 2026-07-15 | 5,773,373 | -0.5% | 1,782,477 | 3.24 |
| 2026-06-30 | 5,799,788 | +6.7% | 1,373,085 | 4.22 |
| 2026-06-15 | 5,437,337 | +2.6% | 1,142,712 | 4.76 |
| 2026-05-29 | 5,300,015 | -1.8% | 917,637 | 5.78 |
| 2026-05-15 | 5,398,804 | +13.1% | 1,052,011 | 5.13 |
| 2026-04-30 | 4,773,214 | -5.2% | 1,186,604 | 4.02 |
| 2026-04-15 | 5,034,063 | -0.4% | 983,971 | 5.12 |
| 2026-03-31 | 5,056,408 | +15.7% | 1,262,297 | 4.01 |
| 2026-03-13 | 4,369,615 | -4.4% | 1,045,068 | 4.18 |
| 2026-02-27 | 4,572,652 | -12.8% | 1,025,083 | 4.46 |
| 2026-02-13 | 5,244,475 | -0.7% | 1,872,268 | 2.80 |
| 2026-01-30 | 5,282,136 | -5.1% | 1,442,702 | 3.66 |
| 2026-01-15 | 5,565,961 | +0.6% | 1,496,902 | 3.72 |
| 2025-12-31 | 5,532,159 | +32.2% | 1,911,674 | 2.89 |
| 2025-12-15 | 4,184,652 | +5.7% | 1,310,181 | 3.19 |
| 2025-11-28 | 3,960,190 | -7.5% | 969,124 | 4.09 |
| 2025-11-14 | 4,279,250 | +13.5% | 953,633 | 4.49 |
| 2025-10-31 | 3,769,098 | -5.6% | 1,127,221 | 3.34 |
| 2025-10-15 | 3,993,922 | +13.9% | 1,146,101 | 3.48 |
| 2025-09-30 | 3,507,540 | -5.7% | 1,043,702 | 3.36 |
| 2025-09-15 | 3,718,643 | -6.4% | 1,220,959 | 3.05 |
| 2025-08-29 | 3,973,434 | +15.9% | 1,064,147 | 3.73 |
Daily short volume
FINRA Reg SHO, last 60 sessions. JSONAs of 11 September 2026, the short share of ALNY volume is 67.2%, down 7.6 points over the last five sessions. Over the last 52 readings it ranged from 18.6% (31 July 2026) to 83.2% (8 September 2026). The latest reading is 12.2 points above the 30-session average of 55.0%, on 498K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-09-11 | 335K | 498K | 67.2% | 0 |
| 2026-09-10 | 478K | 646K | 74.0% | 11,931 |
| 2026-09-09 | 458K | 614K | 74.6% | 51 |
| 2026-09-08 | 694K | 834K | 83.2% | 38,876 |
| 2026-09-04 | 527K | 673K | 78.3% | 0 |
| 2026-09-03 | 524K | 701K | 74.7% | 0 |
| 2026-09-02 | 928K | 1.4M | 67.0% | 49 |
| 2026-09-01 | 574K | 834K | 68.8% | 150 |
| 2026-08-31 | 456K | 605K | 75.3% | 5,181 |
| 2026-08-28 | 559K | 821K | 68.1% | 351 |
| 2026-08-27 | 398K | 717K | 55.5% | 752 |
| 2026-08-26 | 216K | 502K | 43.0% | 0 |
| 2026-08-25 | 253K | 674K | 37.5% | 6,992 |
| 2026-08-24 | 540K | 914K | 59.1% | 0 |
| 2026-08-21 | 650K | 897K | 72.5% | 0 |
| 2026-08-20 | 567K | 908K | 62.5% | 746 |
| 2026-08-19 | 568K | 921K | 61.6% | 161 |
| 2026-08-18 | 426K | 716K | 59.5% | 5,203 |
| 2026-08-17 | 523K | 728K | 71.9% | 59 |
| 2026-08-14 | 364K | 708K | 51.3% | 6,384 |
| 2026-08-13 | 289K | 705K | 41.0% | 20 |
| 2026-08-12 | 243K | 538K | 45.1% | 250 |
| 2026-08-11 | 125K | 610K | 20.4% | 109 |
| 2026-08-10 | 204K | 563K | 36.2% | 17,026 |
| 2026-08-07 | 281K | 769K | 36.6% | 18 |
| 2026-08-06 | 485K | 927K | 52.3% | 352 |
| 2026-08-05 | 495K | 1.4M | 36.1% | 156 |
| 2026-08-04 | 553K | 1.5M | 37.1% | 825 |
| 2026-08-03 | 326K | 1.6M | 20.6% | 0 |
| 2026-07-31 | 433K | 2.3M | 18.6% | 30,447 |
Fails to deliver
SEC, by settlement date. JSONAs of 12 August 2026, the fails-to-deliver balance in ALNY is 2 shares, down 14 shares over the last settlement date. Over the last 52 readings it ranged from 1 share (25 November 2025) to 22,234 shares (12 June 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-08-12 | 2 | $221.20 | $442 |
| 2026-08-05 | 16 | $219.00 | $4K |
| 2026-07-31 | 65 | $205.48 | $13K |
| 2026-07-28 | 100 | $278.40 | $28K |
| 2026-07-16 | 8 | $279.14 | $2K |
| 2026-07-13 | 4 | $298.76 | $1K |
| 2026-07-09 | 3,683 | $323.50 | $1.2M |
| 2026-07-08 | 3,745 | $321.59 | $1.2M |
| 2026-07-01 | 3,004 | $301.03 | $904K |
| 2026-06-22 | 6 | $278.09 | $2K |
| 2026-06-18 | 4 | $282.72 | $1K |
| 2026-06-12 | 22,234 | $289.39 | $6.4M |
| 2026-06-09 | 75 | $292.16 | $22K |
| 2026-06-08 | 6,664 | $303.05 | $2.0M |
| 2026-06-05 | 6,912 | $303.64 | $2.1M |
| 2026-04-24 | 15 | $313.79 | $5K |
| 2026-04-14 | 3 | $333.00 | $999 |
| 2026-04-10 | 598 | $321.28 | $192K |
| 2026-04-08 | 489 | $319.52 | $156K |
| 2026-04-07 | 486 | $330.34 | $161K |
| 2026-04-06 | 47 | $318.85 | $15K |
| 2026-03-31 | 450 | $316.09 | $142K |
| 2026-03-23 | 4,372 | $312.17 | $1.4M |
| 2026-03-19 | 3 | $314.80 | $944 |
| 2026-03-16 | 583 | $313.41 | $183K |
| 2026-03-03 | 14,083 | $325.07 | $4.6M |
| 2026-03-02 | 2,101 | $332.92 | $699K |
| 2026-02-12 | 1 | $322.28 | $322 |
| 2026-02-09 | 2 | $328.16 | $656 |
| 2026-02-02 | 30 | $338.06 | $10K |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONNo open-market insider trades were reported for ALNY in the last 90 days. The most recent filings are listed below; grants and option exercises carry a weaker signal than voluntary trades. Latest filing: PYOTT DAVID E I on 2026-06-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | PYOTT DAVID E I | n/a | Sell | 17 | $302.65 | $5K | 2K |
| 2026-06-01 | PYOTT DAVID E I | n/a | Sell | 495 | $300.72 | $149K | 2K |
| 2026-06-01 | PYOTT DAVID E I | n/a | Sell | 1K | $299.87 | $366K | 2K |
| 2026-06-01 | PYOTT DAVID E I | n/a | Sell | 1K | $298.91 | $351K | 3K |
| 2026-06-01 | PYOTT DAVID E I | n/a | Sell | 921 | $297.71 | $274K | 4K |
| 2026-06-01 | PYOTT DAVID E I | n/a | Option exercise | 4K | $0.00 | $0 | 5K |
| 2026-05-20 | Sigal Charles Elliott | n/a | Grant | 671 | $0.00 | $0 | 1K |
| 2026-05-20 | SCHULMAN AMY W | n/a | Grant | 838 | $0.00 | $0 | 24K |
| 2026-05-20 | Reitan Colleen F | n/a | Grant | 671 | $0.00 | $0 | 1K |
| 2026-05-20 | PYOTT DAVID E I | n/a | Grant | 671 | $0.00 | $0 | 2K |
| 2026-05-20 | KELLOGG PETER N | n/a | Grant | 671 | $0.00 | $0 | 1K |
| 2026-05-20 | HAMBURG MARGARET A | n/a | Grant | 671 | $0.00 | $0 | 2K |
| 2026-05-20 | BRANDICOURT OLIVIER | n/a | Grant | 671 | $0.00 | $0 | 1K |
| 2026-05-20 | Ausiello Dennis A | n/a | Grant | 671 | $0.00 | $0 | 2K |
| 2026-05-20 | Arbuckle Stuart A | n/a | Grant | 671 | $0.00 | $0 | 671 |
| 2026-05-13 | SCHULMAN AMY W | n/a | Option exercise | 11K | $70.20 | $790K | 23K |
| 2026-04-06 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 199 | $333.94 | $66K | 9K |
| 2026-04-06 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 293 | $331.89 | $97K | 10K |
| 2026-04-06 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 829 | $330.46 | $274K | 10K |
| 2026-04-06 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 909 | $329.76 | $300K | 11K |
| 2026-04-06 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 56 | $320.14 | $18K | 12K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 8 | $325.49 | $3K | 12K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 81 | $323.64 | $26K | 12K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 245 | $322.86 | $79K | 12K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 224 | $321.64 | $72K | 12K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 147 | $320.62 | $47K | 12K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 86 | $319.69 | $27K | 12K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 209 | $318.47 | $67K | 13K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 359 | $317.44 | $114K | 13K |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | Sell | 265 | $316.61 | $84K | 13K |
| 2026-03-05 | Garg Pushkal | EVP Chief R&D | Sell | 500 | $326.08 | $163K | 19K |
| 2026-03-05 | Garg Pushkal | EVP Chief R&D | Sell | 510 | $324.59 | $166K | 19K |
| 2026-03-05 | Garg Pushkal | EVP Chief R&D | Sell | 740 | $323.55 | $239K | 20K |
| 2026-03-05 | Garg Pushkal | EVP Chief R&D | Sell | 654 | $322.33 | $211K | 20K |
| 2026-03-05 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 153 | $326.24 | $50K | 21K |
| 2026-03-05 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 148 | $324.60 | $48K | 21K |
| 2026-03-05 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 233 | $323.25 | $75K | 21K |
| 2026-03-05 | Fitzgerald Kevin Joseph | CSO & EVP, Head of Research | Sell | 124 | $321.81 | $40K | 21K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 208 | $325.67 | $68K | 21K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 272 | $324.88 | $88K | 21K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 767 | $323.84 | $248K | 22K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 350 | $323.01 | $113K | 22K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 289 | $321.82 | $93K | 23K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 215 | $320.81 | $69K | 23K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 102 | $320.01 | $33K | 23K |
| 2026-03-04 | Garg Pushkal | EVP Chief R&D | Sell | 106 | $319.03 | $34K | 23K |
| 2026-03-04 | Greenstreet Yvonne | Chief Executive Officer | Sell | 265 | $325.67 | $86K | 96K |
| 2026-03-04 | Greenstreet Yvonne | Chief Executive Officer | Sell | 345 | $324.88 | $112K | 96K |
| 2026-03-04 | Greenstreet Yvonne | Chief Executive Officer | Sell | 973 | $323.84 | $315K | 96K |
| 2026-03-04 | Greenstreet Yvonne | Chief Executive Officer | Sell | 444 | $323.01 | $143K | 97K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are the rarer, stronger signal.
13F holders
Tracked managers holding ALNY at their latest 13F. JSON8 of the 30 tracked managers held ALNY at their latest 13F, $1.49B in total at quarter-end prices. Two Sigma Investments is the largest at $564.7M (0.4% of its portfolio) as of 2026-06-30. Over the prior quarter 3 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Two Sigma Investments | 2026-06-30 | 1.9M | $564.7M | 0.41% | -4.1M |
| D. E. Shaw & Co. | 2026-06-30 | 1.5M | $461.9M | 0.22% | +60K |
| AQR Capital Management | 2026-06-30 | 728K | $219.0M | 0.08% | -185K |
| Millennium Management | 2026-06-30 | 379K | $114.2M | 0.04% | new or n/a |
| Citadel Advisors | 2026-06-30 | 315K | $94.9M | 0.01% | +204K |
| Bridgewater Associates | 2026-06-30 | 100K | $30.0M | 0.12% | -7K |
| Fisher Asset Management | 2026-06-30 | 6K | $1.9M | 0.00% | +207 |
| Point72 Asset Management | 2026-06-30 | 2K | $662K | 0.00% | -4K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 2026 (quarter ended 2026-06-30) ALNYLAM PHARMACEUTICALS, INC. reported revenue of $1.29B, up 66.9% from the same quarter a year earlier, and net income of $164.5M (1.21 diluted EPS). In FY 2025 it generated $524.1M of operating cash flow.
- Cash
- $1.71B
- Equity
- $1.35B
- Total assets
- $5.56B
- Shares outstanding
- 133,809,118
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $1.29B | $164.5M | 12.7% | 1.21 |
| Q1 2026 | 2026-03-31 | n/a | $206.0M | n/a | n/a |
| Q4 2025derived | 2025-12-31 | n/a | n/a | n/a | n/a |
| Q3 2025 | 2025-09-30 | $1.25B | $251.1M | 20.1% | 1.84 |
| Q2 2025 | 2025-06-30 | $773.7M | -$72.2M | -9.3% | -0.55 |
| Q1 2025 | 2025-03-31 | n/a | -$18.3M | n/a | n/a |
| Q4 2024derived | 2024-12-31 | $593.2M | n/a | n/a | n/a |
| Q3 2024 | 2024-09-30 | $500.9M | -$111.6M | -22.3% | -0.87 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $3.71B | n/a | $524.1M | $58.7M | n/a | n/a |
| FY 2024 | 2024-12-31 | $2.25B | n/a | -$8.3M | $34.3M | n/a | n/a |
| FY 2023 | 2023-12-31 | $1.83B | n/a | $104.2M | $62.2M | n/a | n/a |
| FY 2022 | 2022-12-31 | $1.04B | n/a | -$541.3M | $72.1M | n/a | n/a |
| FY 2021 | 2021-12-31 | $844.3M | n/a | -$641.7M | $76.4M | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are cash paid to repurchase common stock in the year (XBRL PaymentsForRepurchaseOfCommonStock), not authorizations. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-24 from the cover page.
What this page is
ALNYLAM PHARMACEUTICALS, INC. in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page pulls every series the site collects for one ticker onto one URL, keyed by the SEC's own ticker list, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a summary sentence built from the rows (last value, change, range with dates) and its own JSON and CSV links. Nothing on the page is written by a model; the sentences change only when the data does. A page exists only for companies with data in at least two series, and every section says when its source last updated.
This page follows ALNYLAM PHARMACEUTICALS, INC. (ALNY), SEC CIK 1178670, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and method
- Short interest
- FINRA consolidated short interestTwice a month, about eight business days after settlement. Latest 2026-08-14.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesEvery trading day, loaded the following morning. Latest 2026-09-11.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataTwice a month, a few weeks after the half month ends. Latest 2026-08-12.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRQuarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC XBRL company factsRefreshed weekly from the SEC's structured data; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Insider trades
- SEC EDGAR Form 4EDGAR read every 30 minutes; filings are due two business days after the trade. Latest 2026-06-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1178670Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 30 requests a minute without a key, 120 a minute with a key from a free account.
Data checks. Every dataset is checked against its source once a day. This dataset passed the last run, 13 Sep 05:40 UTC.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a crowded short are the combination that has historically preceded squeezes; insider sells next to a crowded short are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUNITED THERAPEUTICS Corp
- CPIXCUMBERLAND PHARMACEUTICALS INC
- LLYELI LILLY & Co
- PTCTPTC THERAPEUTICS, INC.
- MDGLMADRIGAL PHARMACEUTICALS, INC.
- ONCBeOne Medicines Ltd.
- IONSIONIS PHARMACEUTICALS INC
- INSMINSMED Inc
- CORTCORCEPT THERAPEUTICS INC
- ROIVRoivant Sciences Ltd.
- BBIOBridgeBio Pharma, Inc.
- CYTKCYTOKINETICS INC
- VRTXVERTEX PHARMACEUTICALS INC / MA
- LGNDLIGAND PHARMACEUTICALS INC
- LQDALiquidia Corp
- SIONSionna Therapeutics, Inc.
- JAZZJazz Pharmaceuticals plc
- BLTEBELITE BIO, INC
- TVTXTravere Therapeutics, Inc.
- PAHCPHIBRO ANIMAL HEALTH CORP
- ARQTArcutis Biotherapeutics, Inc.
- NATRNATURES SUNSHINE PRODUCTS INC
- HOWLWerewolf Therapeutics, Inc.
- JNJJOHNSON & JOHNSON
Datasets
Frequently Asked Questions
How much of ALNY is sold short?
What is ALNY's daily short volume?
Does ALNY have fails to deliver?
Are ALNY insiders buying or selling?
What did ALNY report last quarter?
Which funds hold ALNY?
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.